Regeneron's performance in the first quarter was dismal. The plunge in Eylea sales adversely impacted the top line. Eylea sales have been under pressure for some time now due to competition from ...

This case[1] involves an appeal from Regeneron Pharmaceuticals, Inc.’s (Regeneron) efforts to prevent defendants from marketing biosimilar versions of EYLEA®, a drug used to treat eye diseases ...

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

Faricimab (Vabysmo) showed greater fluid reduction compared with high-dose aflibercept (Eylea) at 12 weeks in matched analyses of diabetic macular edema (DME) and age-related macular degeneration ...

The company's biosimilar strategy also provides a competitive edge. With successful launches of Pavblu (Eylea biosimilar) and Wezlana (Stelara biosimilar), plus upcoming biosimilars for ...

However, even with this setback in mind and the other recent one – the Q1 Eylea miss with worsening outlook, and the above-mentioned business development criticism, I continue to see Regeneron ...

Roche has set a list price of $2,190 per dose, higher than Eylea's $1,850 but potentially a cheaper option for patients who can be stabilised on less frequent doses.

Vabysmo has put up a stellar performance against Eylea. Roche is also looking to diversify its portfolio in the wake of declining sales from legacy drugs (Avastin, Herceptin, MabThera and Actemra ...

The MERLIN study was comparing Beovu to Eylea in 529 wet AMD patients with persistent retinal fluid, and found the two drugs were equivalent on the primary endpoint of best corrected visual acuity ...

“So we continued her on Eylea injection here, her OCT scan passing through the fovea which is pretty much maintained at 20/30, and we continued her on Eylea, and here you can see that she has ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

“So what were the treatment options available? At that point, we had only three drugs available, Avastin, Lucentis, and Eylea. However, you can see the bottom part where we have a long list of ...